Study identifier:D5330C00017
ClinicalTrials.gov identifier:NCT05514132
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Advanced Solid Tumours
Phase 1
No
Ceralasertib, Durvalumab
All
14
Interventional
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Ceralasertib in Combination with Durvalumab This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking. | - |